APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Influenza Virus Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Inactivated Influenza Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025196 pages

Choose your research edition.

Industry ResearchInactivated Influenza Virus Vaccine Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Influenza Virus Vaccine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inactivated Influenza Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Influenza Virus Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Influenza Virus Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Inactivated Influenza Virus Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Inactivated Influenza Virus Vaccine include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Inactivated Influenza Virus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Inactivated Influenza Virus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Inactivated Influenza Virus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inactivated Influenza Virus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Inactivated Influenza Virus Vaccine Segment by Company

CSL

Zhejiang Tian Yuan Biopharmaceutical Co., Ltd

Changchun Institute of Biological Products Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Johnson & Johnson

Mylan

Lanzhou Institute of Biological Products Co., Ltd

Jiangsu Kangrun Biotechnology Co., Ltd

Jiangsu Jindik Biotechnology Co., Ltd

Pfizer

Hualan Bio Vaccines Co., Ltd

GSK

Dalian Yalifeng Biopharmaceutical Co., Ltd

Beijing Kexing Biological Products Co., Ltd

Emmi Chengxin Biopharmaceutical Co., Ltd

AstraZeneca

Sanofi Pasteur

Inactivated Influenza Virus Vaccine Segment by Type

Whole Virus Vaccine

Subunit Vaccine

Inactivated Influenza Virus Vaccine Segment by Application

Hospital

Clinic

Inactivated Influenza Virus Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Inactivated Influenza Virus Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Inactivated Influenza Virus Vaccine Industry Trends Table 2. Inactivated Influenza Virus Vaccine Industry Drivers Table 3. Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges Table 4. Inactivated Influenza Virus Vaccine Industry Restraints Table 5. Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers Table 9. Global Inactivated Influenza Virus Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Inactivated Influenza Virus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Inactivated Influenza Virus Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Inactivated Influenza Virus Vaccine Manufacturers, Product Type & Application Table 13. Global Inactivated Influenza Virus Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Inactivated Influenza Virus Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Whole Virus Vaccine Table 17. Major Manufacturers of Subunit Vaccine Table 18. Global Inactivated Influenza Virus Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Inactivated Influenza Virus Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Global Inactivated Influenza Virus Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 32. Global Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 33. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Inactivated Influenza Virus Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (K Units) Table 37. Global Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (K Units) Table 38. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Inactivated Influenza Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026) & (K Units) Table 42. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Inactivated Influenza Virus Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Inactivated Influenza Virus Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 47. North America Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 48. Europe Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 50. Europe Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 57. Global Inactivated Influenza Virus Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Inactivated Influenza Virus Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Inactivated Influenza Virus Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2027-2032) Table 62. CSL Company Information Table 63. CSL Business Overview Table 64. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. CSL Inactivated Influenza Virus Vaccine Product Portfolio Table 66. CSL Recent Development Table 67. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information Table 68. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview Table 69. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 71. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Development Table 72. Changchun Institute of Biological Products Co., Ltd Company Information Table 73. Changchun Institute of Biological Products Co., Ltd Business Overview Table 74. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 76. Changchun Institute of Biological Products Co., Ltd Recent Development Table 77. Shanghai Institute of Biological Products Co., Ltd Company Information Table 78. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 79. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 81. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Mylan Company Information Table 88. Mylan Business Overview Table 89. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Mylan Inactivated Influenza Virus Vaccine Product Portfolio Table 91. Mylan Recent Development Table 92. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 93. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 94. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 96. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 97. Jiangsu Kangrun Biotechnology Co., Ltd Company Information Table 98. Jiangsu Kangrun Biotechnology Co., Ltd Business Overview Table 99. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 101. Jiangsu Kangrun Biotechnology Co., Ltd Recent Development Table 102. Jiangsu Jindik Biotechnology Co., Ltd Company Information Table 103. Jiangsu Jindik Biotechnology Co., Ltd Business Overview Table 104. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 106. Jiangsu Jindik Biotechnology Co., Ltd Recent Development Table 107. Pfizer Company Information Table 108. Pfizer Business Overview Table 109. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Pfizer Inactivated Influenza Virus Vaccine Product Portfolio Table 111. Pfizer Recent Development Table 112. Hualan Bio Vaccines Co., Ltd Company Information Table 113. Hualan Bio Vaccines Co., Ltd Business Overview Table 114. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 116. Hualan Bio Vaccines Co., Ltd Recent Development Table 117. GSK Company Information Table 118. GSK Business Overview Table 119. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. GSK Inactivated Influenza Virus Vaccine Product Portfolio Table 121. GSK Recent Development Table 122. Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information Table 123. Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview Table 124. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 126. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Development Table 127. Beijing Kexing Biological Products Co., Ltd Company Information Table 128. Beijing Kexing Biological Products Co., Ltd Business Overview Table 129. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 131. Beijing Kexing Biological Products Co., Ltd Recent Development Table 132. Emmi Chengxin Biopharmaceutical Co., Ltd Company Information Table 133. Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview Table 134. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 136. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Development Table 137. AstraZeneca Company Information Table 138. AstraZeneca Business Overview Table 139. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio Table 141. AstraZeneca Recent Development Table 142. Sanofi Pasteur Company Information Table 143. Sanofi Pasteur Business Overview Table 144. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio Table 146. Sanofi Pasteur Recent Development Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Inactivated Influenza Virus Vaccine Distributors List Table 150. Inactivated Influenza Virus Vaccine Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Inactivated Influenza Virus Vaccine Product Image Figure 2. Global Inactivated Influenza Virus Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inactivated Influenza Virus Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Inactivated Influenza Virus Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Inactivated Influenza Virus Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Inactivated Influenza Virus Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Whole Virus Vaccine Image Figure 9. Subunit Vaccine Image Figure 10. Global Inactivated Influenza Virus Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Inactivated Influenza Virus Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Inactivated Influenza Virus Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Inactivated Influenza Virus Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Global Inactivated Influenza Virus Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Inactivated Influenza Virus Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Inactivated Influenza Virus Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Inactivated Influenza Virus Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Inactivated Influenza Virus Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Inactivated Influenza Virus Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Inactivated Influenza Virus Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Inactivated Influenza Virus Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Whole Virus Vaccine
  • Subunit Vaccine
Applications
  • Hospital
  • Clinic
Companies covered
  • CSL
  • Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  • Changchun Institute of Biological Products Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Johnson & Johnson
  • Mylan
  • Lanzhou Institute of Biological Products Co., Ltd
  • Jiangsu Kangrun Biotechnology Co., Ltd
  • Jiangsu Jindik Biotechnology Co., Ltd
  • Pfizer
  • Hualan Bio Vaccines Co., Ltd
  • GSK
  • Dalian Yalifeng Biopharmaceutical Co., Ltd
  • Beijing Kexing Biological Products Co., Ltd
  • Emmi Chengxin Biopharmaceutical Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Inactivated Influenza Virus Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Inactivated Influenza Virus Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Inactivated Influenza Virus Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Inactivated Influenza Virus Vaccine Market Dynamics
  1. 2.1 Inactivated Influenza Virus Vaccine Industry Trends
  2. 2.2 Inactivated Influenza Virus Vaccine Industry Drivers
  3. 2.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Influenza Virus Vaccine Industry Restraints
3 Inactivated Influenza Virus Vaccine Market by Manufacturers
  1. 3.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Inactivated Influenza Virus Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Inactivated Influenza Virus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Inactivated Influenza Virus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Inactivated Influenza Virus Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Inactivated Influenza Virus Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Inactivated Influenza Virus Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Inactivated Influenza Virus Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Inactivated Influenza Virus Vaccine Tier 1, Tier 2, and Tier 3
4 Inactivated Influenza Virus Vaccine Market by Type
  1. 4.1 Inactivated Influenza Virus Vaccine Type Introduction
  2. 4.1.1 Whole Virus Vaccine
  3. 4.1.2 Subunit Vaccine
  4. 4.2 Global Inactivated Influenza Virus Vaccine Sales by Type
  5. 4.2.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Inactivated Influenza Virus Vaccine Revenue by Type
  9. 4.3.1 Global Inactivated Influenza Virus Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2032)
5 Inactivated Influenza Virus Vaccine Market by Application
  1. 5.1 Inactivated Influenza Virus Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Inactivated Influenza Virus Vaccine Sales by Application
  5. 5.2.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Inactivated Influenza Virus Vaccine Revenue by Application
  9. 5.3.1 Global Inactivated Influenza Virus Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2032)
6 Global Inactivated Influenza Virus Vaccine Sales by Region
  1. 6.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Inactivated Influenza Virus Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Inactivated Influenza Virus Vaccine Revenue by Region
  1. 7.1 Global Inactivated Influenza Virus Vaccine Revenue by Region
  2. 7.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Inactivated Influenza Virus Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Inactivated Influenza Virus Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Inactivated Influenza Virus Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Inactivated Influenza Virus Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Inactivated Influenza Virus Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL
  2. 8.1.1 CSL Company Information
  3. 8.1.2 CSL Business Overview
  4. 8.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
  6. 8.1.5 CSL Recent Developments
  7. 8.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  8. 8.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information
  9. 8.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
  10. 8.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  12. 8.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
  13. 8.3 Changchun Institute of Biological Products Co., Ltd
  14. 8.3.1 Changchun Institute of Biological Products Co., Ltd Company Information
  15. 8.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
  16. 8.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  18. 8.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
  19. 8.4 Shanghai Institute of Biological Products Co., Ltd
  20. 8.4.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  21. 8.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  22. 8.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  24. 8.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Lanzhou Institute of Biological Products Co., Ltd
  38. 8.7.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  39. 8.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  40. 8.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  42. 8.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  43. 8.8 Jiangsu Kangrun Biotechnology Co., Ltd
  44. 8.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Company Information
  45. 8.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
  46. 8.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  48. 8.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
  49. 8.9 Jiangsu Jindik Biotechnology Co., Ltd
  50. 8.9.1 Jiangsu Jindik Biotechnology Co., Ltd Company Information
  51. 8.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
  52. 8.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  54. 8.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Hualan Bio Vaccines Co., Ltd
  62. 8.11.1 Hualan Bio Vaccines Co., Ltd Company Information
  63. 8.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
  64. 8.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  66. 8.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
  67. 8.12 GSK
  68. 8.12.1 GSK Company Information
  69. 8.12.2 GSK Business Overview
  70. 8.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
  72. 8.12.5 GSK Recent Developments
  73. 8.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
  74. 8.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information
  75. 8.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
  76. 8.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  78. 8.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
  79. 8.14 Beijing Kexing Biological Products Co., Ltd
  80. 8.14.1 Beijing Kexing Biological Products Co., Ltd Company Information
  81. 8.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
  82. 8.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  84. 8.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
  85. 8.15 Emmi Chengxin Biopharmaceutical Co., Ltd
  86. 8.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Company Information
  87. 8.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
  88. 8.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  90. 8.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 Sanofi Pasteur
  98. 8.17.1 Sanofi Pasteur Company Information
  99. 8.17.2 Sanofi Pasteur Business Overview
  100. 8.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
  102. 8.17.5 Sanofi Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
  2. 9.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Inactivated Influenza Virus Vaccine Production Mode & Process
  6. 9.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Inactivated Influenza Virus Vaccine Distributors
  9. 9.2.3 Inactivated Influenza Virus Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst